文献速递胸部肿瘤

Pralsetinib 治疗 RET 融合阳性非小细胞肺癌(ARROW):多队列开放标签 1/2 期研究

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
PubMed 文献 · Lancet Oncol · 2021-06-09

ARROW 研究为多队列、开放标签 1/2 期试验,评估口服选择性 RET 抑制剂 pralsetinib 在 RET 融合阳性 NSCLC 中的疗效与安全性。经铂类化疗患者客观缓解率 61%(95%CI 50-71),初治患者 70%(95%CI 50-86);常见≥3 级治疗相关不良事件为中性粒细胞减少、高血压和贫血。

要点

  • 经铂类化疗的 RET 融合阳性 NSCLC 患者客观缓解率 61%,初治患者 70%
  • 常见≥3 级治疗相关不良事件为中性粒细胞减少(18%)、高血压(11%)、贫血(10%)
  • Pralsetinib 为每日一次口服、耐受性良好的 RET 融合阳性 NSCLC 治疗选择

核心结论

  • Pralsetinib 是 RET 融合阳性 NSCLC 患者一种耐受性良好、有前景的每日一次口服治疗选择。

研究设计与样本

  • ARROW 为多队列、开放标签 1/2 期研究,在 13 个国家 71 个中心开展。
  • 纳入 ≥18 岁局部晚期或转移性实体瘤(含 RET 融合阳性 NSCLC)、ECOG 0-2(后续修订为 0-1)患者。

主要发现

  • 87 例经铂类化疗且中心判定基线可测量病灶患者中,53 例(61%;95%CI 50-71)出现客观缓解,其中 5 例(6%)完全缓解。
  • 27 例初治且中心判定基线可测量病灶患者中,19 例(70%;95%CI 50-86)出现客观缓解,其中 3 例(11%)完全缓解。
  • 233 例 RET 融合阳性 NSCLC 患者中,常见≥3 级治疗相关不良事件为中性粒细胞减少(43 例[18%])、高血压(26 例[11%])、贫血(24 例[10%]),无治疗相关死亡。

关键数值与推荐

  • 经铂类化疗患者客观缓解率 61%(95%CI 50-71),完全缓解率 6%。
  • 初治患者客观缓解率 70%(95%CI 50-86),完全缓解率 11%。
  • ≥3 级治疗相关不良事件:中性粒细胞减少 18%、高血压 11%、贫血 10%。

临床怎么用

  • 对于 RET 融合阳性 NSCLC,pralsetinib 400 mg 每日一次口服可作为经铂类化疗或不宜标准化疗初治患者的治疗选择。
  • 治疗期间需关注中性粒细胞减少、高血压和贫血等≥3 级治疗相关不良事件。

局限性

  • 本分析为中期分析,初治 RET 融合阳性 NSCLC 患者入组仍在进行中。
  • 疗效分析仅纳入中心判定基线可测量病灶的患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oncogenic alterations in RET have been identified in multiple tumour types, including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC. METHODS: ARROW is a multi-cohort, open-label, phase 1/2 study done at 71 sites (community and academic cancer centres) in 13 countries (Belgium, China, France, Germany, Hong Kong, Italy, Netherlands, Singapore, South Korea, Spain, Taiwan, the UK, and the USA). Patients aged 18 years or older with locally advanced or metastatic solid tumours, including RET fusion-positive NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-2 (later limited to 0-1 in a protocol amendment) were enrolled. In phase 2, patients received 400 mg once-daily oral pralsetinib, and could continue treatment until disease progression, intolerance, withdrawal of consent, or investigator decision. Phase 2 primary endpoints were overall response rate (according to Response Evaluation Criteria in Solid Tumours version 1·1 and assessed by blinded independent central review) and safety. Tumour response was assessed in patients with RET fusion-positive NSCLC and centrally adjudicated baseline measurable disease who had received platinum-based chemotherapy or were treatment-naive because they were ineligible for standard therapy. This ongoing study is registered with ClinicalTrials.gov, NCT03037385, and enrolment of patients with treatment-naive RET fusion-positive NSCLC was ongoing at the time of this interim analysis. FINDINGS: Of 233 patients with RET fusion-positive NSCLC enrolled between March 17, 2017, and May 22, 2020 (data cutoff), 92 with previous platinum-based chemotherapy and 29 who were treatment-naive received pralsetinib before July 11, 2019 (efficacy enrolment cutoff); 87 previously treated patients and 27 treatment-naive patients had centrally adjudicated baseline measurable disease. Overall responses were recorded in 53 (61%; 95% CI 50-71) of 87 patients with previous platinum-based chemotherapy, including five (6%) patients with a complete response; and 19 (70%; 50-86) of 27 treatment-naive patients, including three (11%) with a complete response. In 233 patients with RET fusion-positive NSCLC, common grade 3 or worse treatment-related adverse events were neutropenia (43 patients [18%]), hypertension (26 [11%]), and anaemia (24 [10%]); there were no treatment-related deaths in this population. INTERPRETATION: Pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC. FUNDING: Blueprint Medicines.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021. PMID: 34118197. doi:10.1016/S1470-2045(21)00247-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。